scholarly journals Do patients benefit from participating in the German skin cancer screening programme?

2022 ◽  
Vol 186 (1) ◽  
Keyword(s):  
Cancer Screening ◽  
Skin Cancer ◽  
Screening Programme ◽  
Skin Cancer Screening ◽  
Cancer Screening Programme

The many unanswered questions related to the German skin cancer screening programme

2016 ◽  
Vol 64 ◽  
pp. 83-88 ◽  
Author(s):  
Andreas Stang ◽  
Claus Garbe ◽  
Philippe Autier ◽  
Karl-Heinz Jöckel
Keyword(s):  
Cancer Screening ◽  
Skin Cancer ◽  
Screening Programme ◽  
Skin Cancer Screening ◽  
Cancer Screening Programme ◽  
The Many

Effects of the German skin cancer screening programme on melanoma incidence and indicators of disease severity

2016 ◽  
Vol 175 (5) ◽  
pp. 912-919 ◽  
Author(s):  
F. Trautmann ◽  
F. Meier ◽  
A. Seidler ◽  
J. Schmitt
Keyword(s):  
Cancer Screening ◽  
Skin Cancer ◽  
Disease Severity ◽  
Screening Programme ◽  
Skin Cancer Screening ◽  
Melanoma Incidence ◽  
Cancer Screening Programme

The use of targeted and non-targeted advertising to enrich skin cancer screening samples

1996 ◽  
Vol 135 (2) ◽  
pp. 268-274 ◽  
Author(s):  
P. KATRIS ◽  
R.J. DONOVAN ◽  
B.N. GRAY
Keyword(s):  
Cancer Screening ◽  
Skin Cancer ◽  
Skin Cancer Screening ◽  
Targeted Advertising

Skin Cancer Screening Prevalence Inching Higher

2009 ◽  
Vol 40 (4) ◽  
pp. 25
Author(s):  
BRUCE JANCIN
Keyword(s):  
Cancer Screening ◽  
Skin Cancer ◽  
Skin Cancer Screening

Skin Cancer Screening Prevalence Inches Up

2009 ◽  
Vol 42 (8) ◽  
pp. 20
Author(s):  
BRUCE JANCIN
Keyword(s):  
Cancer Screening ◽  
Skin Cancer ◽  
Skin Cancer Screening

Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort

2016 ◽  
Vol 25 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Ashley D. Bond ◽  
Michael D. Burkitt ◽  
David Sawbridge ◽  
Bernard M. Corfe ◽  
Chris S. Probert
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Pyruvate Kinase ◽  
Predictive Value ◽  
Screening Programme ◽  
Occult Blood ◽  
Faecal Occult ◽  
Faecal Samples ◽  
Cancer Screening Programme ◽  
Bowel Cancer Screening

Background & Aims: Colorectal cancer screening programmes that target detection and excision of adenomatous colonic polyps have been shown to reduce colorectal cancer related mortality. Many screening programmes include an initial faecal occult blood test (FOBt) prior to colonoscopy. To refine the selection of patients for colonoscopy other faecal-based diagnostic tools have been proposed, including tumour M2-pyruvate kinase (tM2-PK). To determine whether tM2-PK quantification may have a role in diverse settings we have assessed the assay in a cohort of patients derived from both the England bowel cancer screening programme (BCSP) and symptomatic individuals presenting to secondary care. Method. Patients undergoing colonoscopy provided faecal samples prior to bowel preparation. Faecal tM2-PK concentrations were measured by ELISA. Sensitivity, specificity, positive predictive value, negative predictive value and ROC analyses were calculated. Results. Ninety-six patients returned faecal samples: 50 of these with adenomas and 7 with cancer. Median age was 68. Median faecal tM2-PK concentration was 3.8 U/mL for individuals without neoplastic findings at colonoscopy, 7.7 U/mL in those with adenomas and 24.4 U/mL in subjects with colorectal cancer (both, p=0.01). ROC analysis demonstrated an AUROC of 0.66 (sensitivity 72.4%, specificity 48.7%, positive predictive value 67.7%, negative predictive value 36.7%). Amongst BCSP patients with a prior positive FOBt faecal tM2-PK was more abundant (median 6.4 U/mL, p=0.03) and its diagnostic accuracy was greater (AUROC 0.82). Conclusion. Our findings confirm that faecal tM2-PK ELISA may have utility as an adjunct to FOBt in a screening context, but do not support its use in symptomatic patients. Abbreviations: BCSP: Bowel cancer screening programme; EMR: Endoscopic mucosal resection; FAP: Familial adenomatous polyposis; FOBt: Faecal occult blood testing; NHS: National Health Service; tM2-PK: tumour M2-pyruvate kinase.

Sign in / Sign up

Export Citation Format

Share Document